Opinion
Video
Author(s):
Comprehensive insights on treatment considerations and managing immunotherapy-related adverse effects for patients with bladder cancer.
This is a modal window.
Beginning of dialog window. Escape will cancel and close the window.
End of dialog window.
This is a modal window. This modal can be closed by pressing the Escape key or activating the close button.
CHAI biomarkers demonstrate prognostic utility for high-grade Ta NMIBC
Dr. Schwen on focal therapies for prostate cancer
Cleveland Clinic is First to Use Wireless, Catheter-Free Device to Monitor Bladder Dysfunction in Patients
Bladder Cancer Awareness Month: Dr. Kamat highlights the state of bladder cancer care
En bloc resection of bladder tumor: Is it the way forward?
Survey: New NMIBC treatments face slow uptake
Is there a difference between MD and DO in urology?
64Cu-SAR-Bombesin shows efficacy in detecting prostate cancer recurrence
From prep to follow-up: Key considerations for administering onabotulinumtoxinA